Highlights

  • Resilience obtains long-term debt financing of up to USD 825M from Oak Hill Advisors
  • Capital to accelerate CDMO growth and enhance manufacturing in Cincinnati and Toronto
  • Financing includes USD 600M first lien commitment, with USD 525M to be funded in Q4

Resilience, a technology-driven biomanufacturing company, announced it has secured long-term debt financing of up to USD 825M from Oak Hill Advisors (NASDAQ:TROW) to support its contract development and manufacturing organization (CDMO) operations. The funding is intended to strengthen the company’s financial position and advance its growth initiatives across key facilities in Cincinnati and Toronto.

The capital will enable Resilience to expand its manufacturing capacity and capabilities, particularly in sterile drug production and other high-demand biopharmaceutical segments.

Expanding CDMO Manufacturing Capabilities

Resilience stated that financing will help scale its biomanufacturing infrastructure and support domestic production of biologics and aseptic drug products. The company is currently expanding its Cincinnati facility, which is expected to become one of the largest sterile injectable and device assembly and packaging operations in North America.

Financing Terms and Transaction Details

The financing structure includes a USD 600M first lien commitment from OHA. The first tranche of USD 525M is expected to be funded during the fourth quarter of 2025, with additional funding available in later years upon meeting standard conditions.

Alongside the financing, Resilience has resolved lease obligations tied to underutilized sites, further improving its financial flexibility.

Joe Goldschmid, Managing Director at OHA, stated: “We believe Resilience is uniquely positioned to scale its advanced manufacturing capabilities and meet the increasing demand for complex medicines. Our investment reflects conviction in the company’s leadership team, strategic positioning and ability to generate long-term value in a sector undergoing rapid transformation. We look forward to supporting Resilience as it expands its footprint and strengthens its role in the global biomanufacturing ecosystem.”

About Resilience

Resilience is a North American CDMO offering scalable manufacturing solutions for biologics, cell-based therapies, and aseptic drug products. The company partners with biopharmaceutical developers to deliver advanced therapies efficiently and reliably.

About Oak Hill Advisors

Oak Hill Advisors (OHA) is a global alternative asset manager with approximately USD 98B in assets under management. The firm specializes in credit-focused investments across private credit, distressed debt, high-yield bonds, and leveraged loans.